相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma?
R. Sabatier et al.
ANNALS OF ONCOLOGY (2012)
Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma
Carlos H. Barrios et al.
CANCER (2012)
Tyrosine Kinase Inhibitors Noncompetitively Inhibit MCT8-Mediated Iodothyronine Transport
Doreen Braun et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study
Jonas Bergh et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Targeted Therapies for Renal Cell Carcinoma: Review of Adverse Event Management Strategies
Tim Eisen et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study
J. J. Biagi et al.
ANNALS OF ONCOLOGY (2011)
Hypothyroidism in Patients With Renal Cell Carcinoma Blessing or Curse?
Manuela Schmidinger et al.
CANCER (2011)
Sunitinib Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel for First-Line Treatment of Patients With Advanced Breast Cancer: A Phase III, Randomized, Open-Label Trial
Nicholas J. Robert et al.
CLINICAL BREAST CANCER (2011)
Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: A meta-analysis of clinical trials
Fabio A. B. Schutz et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2011)
Phase II Trial of Sunitinib Maintenance Therapy After Platinum-Based Chemotherapy in Patients with Extensive-Stage Small Cell Lung Cancer
Bryan J. Schneider et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Phase II Study of Sunitinib in Patients with Non-small Cell Lung Cancer and Irradiated Brain Metastases
Silvia Novello et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group
Rena Buckstein et al.
LEUKEMIA & LYMPHOMA (2011)
Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer
Radj Gervais et al.
LUNG CANCER (2011)
Sunitinib in pretreated advanced non-small-cell lung carcinoma: a primary result from Asian population
Gu Ping et al.
MEDICAL ONCOLOGY (2011)
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors.
Eric Raymond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib
L. M. Riesenbeck et al.
WORLD JOURNAL OF UROLOGY (2011)
SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer
E. L. Mayer et al.
ANNALS OF ONCOLOGY (2010)
Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer
Carlos H. Barrios et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer
George Fountzilas et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184
Helen J. Mackay et al.
GYNECOLOGIC ONCOLOGY (2010)
Phase II Study of Sunitinib in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: GORTEC 2006-01
Jean-Pascal H. Machiels et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Risk of Arterial Thromboembolic Events With Sunitinib and Sorafenib: A Systematic Review and Meta-Analysis of Clinical Trials
Toni K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia
Tait Shanafelt et al.
LEUKEMIA & LYMPHOMA (2010)
Continuous Sunitinib Treatment in Patients with Advanced Hepatocellular Carcinoma: A Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) Multicenter Phase II Trial (SAKK 77/06)
Dieter Koeberle et al.
ONCOLOGIST (2010)
How Does Sunitinib Cause Hypothyroidism?
Jerome M. Hershman et al.
THYROID (2010)
Sunitinib Induces Hypothyroidism with a Markedly Reduced Vascularity
Noriko Makita et al.
THYROID (2010)
Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: Systematic review and meta-analysis
Xiaolei Zhu et al.
ACTA ONCOLOGICA (2009)
Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers
Loukas F. Kontovinis et al.
BMC CANCER (2009)
Risk of Hand-Foot Skin Reaction with the Multitargeted Kinase Inhibitor Sunitinib in Patients with Renal Cell and Non-Renal Cell Carcinoma: A Meta-analysis
David Chu et al.
CLINICAL GENITOURINARY CANCER (2009)
Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure
S. George et al.
EUROPEAN JOURNAL OF CANCER (2009)
Tyrosine kinase inhibitors and modifications of thyroid function tests: a review
Frederic Illouz et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2009)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2009)
Multicenter Phase II Trial of Sunitinib in the Treatment of Nongastrointestinal Stromal Tumor Sarcomas
Suzanne George et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials
Youjin Je et al.
LANCET ONCOLOGY (2009)
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial
Martin E. Gore et al.
LANCET ONCOLOGY (2009)
Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy
Francesco Torino et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Risk of hand-foot skin reaction with sorafenibo: A systematic review and metes-analysis
David Chu et al.
ACTA ONCOLOGICA (2008)
The clinical implications of sunitinib-induced hypothyroidism:: a prospective evaluation
P. Wolter et al.
BRITISH JOURNAL OF CANCER (2008)
Thyrotoxicosis during sunitinib treatment for renal cell carcinoma
Mathis Grossmann et al.
CLINICAL ENDOCRINOLOGY (2008)
Evaluation of thyroid dysfunction as a candidate surrogate marker for efficacy of sunitinib in patients (pts) with advanced renal cell cancer (RCC)
P. Wolter et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma
Brian I. Rini et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis
Shenhong Wu et al.
LANCET ONCOLOGY (2008)
Effect of sunitinib on growth and function of FRTL-5 thyroid cells
Andrew K. Salem et al.
THYROID (2008)
A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake
Deborah Mannavola et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib
Darren R. Feldman et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity
Elaine Wong et al.
THYROID (2007)
Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib
Brian I. Rini et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors
Jayesh Desai et al.
ANNALS OF INTERNAL MEDICINE (2006)
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
George D. Demetri et al.
LANCET (2006)
VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature
T Kamba et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2006)
Tyrosine kinases as targets for cancer therapy
DS Krause et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Subclinical thyroid disease - Scientific review and guidelines for diagnosis and management
MI Surks et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Publication and related bias in meta-analysis: Power of statistical tests and prevalence in the literature
JAC Sterne et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2000)